Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
28 studies found for:    "Wiskott Aldrich syndrome"
Show Display Options
Rank Status Study
21 Completed Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Conditions: Immunologic Deficiency Syndrome;   Agammaglobulinemia;   Severe Combined Immunodeficiency;   Wiskott-Aldrich Syndrome;   Common Variable Immunodeficiency
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Dextrose, 5% in Water
22 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
23 Completed Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder
Conditions: The Follow-up Duration Was 1-8 Years.;   The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,;   Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,;   Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary;   System and Hematuria.
Interventions: Drug: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution;   Drug: cephalosporin with chemotherapeutics
24 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Nonmalignant Neoplasm
Interventions: Drug: treosulfan;   Drug: fludarabine phosphate;   Biological: anti-thymocyte globulin;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
25 Recruiting Reduced Intensity Conditioning in Patients Aged ≤30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
26 Completed Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Condition: Blood Coagulation Disorders
Intervention:
27 Recruiting Molecular and Clinical Studies of Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndrome
Intervention:
28 Completed Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Condition: Primary Immune Deficiency Disease
Intervention: Biological: Flebogamma 5% DIF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-28) Next Page   
Indicates status has not been verified in more than two years